Clara Mayo

Dr. Clara Mayo


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MVMarta Vives-Usano
Marta Vives-Usano
BPBeatriz García Pelaez
Beatriz García Pelaez
RRRUTH ROMAN-LLADO
RUTH ROMAN-LLADO
MIMónica Garzón Ibañez
Mónica Garzón Ibañez
EAErika Aldeguer
Erika Aldeguer
CMClara Mayo
Clara Mayo
Somatic copy number variations (CNV; i.e., amplifications and deletions) have been implicated in the origin and development of multiple cancers and some of these aberrations are designated targets for therapies. Although FISH is still considered the gold standard for CNV detection, the increasing number of potentially druggable amplifications to be assessed makes a gene-by-gene approach time- and tissue-consuming. Here we investigated the potential of next generation sequencing (NGS) custom panels to simultaneously determine CNVs across FFPE solid tumor samples. DNA was purified from cell lines and FFPE samples and analyzed by NGS sequencing using a 20-gene custom panel in the GeneReader Platform®. CNVs were identified using an in-house algorithm based on the UMI read coverage. Retrospective validation of in-house algorithm to identify CNVs showed 97.1% concordance rate with the NGS custom panel. The prospective analysis was performed in a cohort of 243 FFPE samples from patients arriving at our hospital, which included 74 NSCLC tumors, 148 CRC tumors, and 21 other tumors. Of them, 33% presented CNVs by NGS and in 14 cases (5.9%) the CNV was the only alteration detected. We have identified CNV alterations in about one-third of our cohort, including FGFR1, CDK6, CDK4, EGFR, MET, ERBB2, BRAF, or KRAS. Our work highlights the need to include CNV testing as a part of routine NGS analysis in order to uncover clinically relevant gene amplifications that can guide the selection of therapies.

Verified
Journal Article
Open access
PDF file
RRRUTH ROMAN-LLADO
RUTH ROMAN-LLADO
CECristina Esteban
Cristina Esteban
NJNúria Jordana-Ariza
Núria Jordana-Ariza
JRJaume Roca-Arias
Jaume Roca-Arias
SRSonia Rodríguez
Sonia Rodríguez
Miguel Ángel Molina-VilaMiguel Ángel Molina-Vila
Miguel Ángel Molina-Vila
Genetic and drug sensitivity assays on primary cultures are not only of basic but also of translational interest and could eventually aid oncologists in the selection of treatments. However, cancer cells need to be identified and differentiated from the non-tumor cells always present in primary cultures. Also, successive passages can change the proportions of these two subpopulations. In this study, we propose fluorescence in situ hybridization (FISH) analysis on cell smears to determine the presence of tumor cells in primary cultures obtained from patients carrying translocations or copy number gains. FISH proved to be an easy, fast, economic, and reliable method of characterizing cell populations, which could be used repeatedly at different passages to monitor variations and to confirm the maintenance of translocations and copy number gains throughout the culture process.

3 May 2020 in Current Oncology Reports
Verified
Journal Article
Open access
PDF file
JBJillian Wilhelmina Paulina Bracht
Jillian Wilhelmina Paulina Bracht
CMClara Mayo
Clara Mayo
JBJordi Berenguer
Jordi Berenguer
NKNiki Karachaliou
Niki Karachaliou
Rafael RosellRafael Rosell
Rafael Rosell
The original version of this review article unfortunately contained a mistake in the Funding section.

1 January 2018 in Translational Cancer Research
Verified
Journal Article
Open access
PDF file
CMClara Mayo
Clara Mayo
MGMónica Garzón-Ibañez
Mónica Garzón-Ibañez
NJNúria Jordana-Ariza
Núria Jordana-Ariza
SVSantiago Viteri-Ramírez
Santiago Viteri-Ramírez
IMIrene Moya-Horno
Irene Moya-Horno
MMMiguel Ángel Molina-Vila
Miguel Ángel Molina-Vila
Background: In a significant percentage of advanced non-small cell lung cancer (NSCLC) patients, tumor tissue is unavailable or insufficient for genetic analyses at time to progression. We prospectively analyzed the appearance of genetic alterations associated with resistance in liquid biopsies of advanced NSCLC patients progressing to targeted therapies using the NGS platform. Methods: A total of 24 NSCLC patients were included in the study, 22 progressing to tyrosine kinase inhibitors and two to other treatments. Liquid biopsies samples were obtained and analyzed using the GeneReadTM QIAact Lung DNA UMI Panel, designed to enrich specific target regions and containing 550 variant positions in 19 selected genes frequently altered in lung cancer tumors. Previously, a retrospective validation of the panel was performed in clinical samples. Results: Of the 21 patients progressing to tyrosine kinase inhibitors with valid results in liquid biopsy, NGS analysis identified a potential mechanism of resistance in 12 (57%). The most common were acquired mutations in ALK and EGFR, which appeared in 8/21 patients (38%), followed by amplifications in 5/21 patients (24%), and KRAS mutations in one patient (5%). Loss of the p.T790M was also identified in two patients progressing to osimertinib. Three of the 21 (14%) patients presented two or more concomitant alterations associated with resistance. Finally, an EGFR amplification was found in the only patient progressing to immunotherapy included in the study. Conclusions: NGS analysis in liquid biopsies of patients progressing to targeted therapies using the GeneReader platform is feasible and can help the oncologist to make treatment decisions.